RecruitingPhase 4NCT03975829
Pediatric Long-Term Follow-up and Rollover Study
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)
Sponsor
Novartis Pharmaceuticals
Enrollment
165 participants
Start Date
Nov 4, 2019
Study Type
INTERVENTIONAL
Conditions
Neurofibromatosis Type 1GlioblastomaAnaplastic AstrocytomaAstrocytomaAnaplastic OligodendrogliomaPilocytic AstrocytomaPleomorphic XanthoastrocytomaAnaplastic Pleomorphic XanthoastrocytomaDiffuse AstrocytomaGangliogliomaOligodendroglioma, ChildhoodGiant Cell AstrocytomaAngiocentric GliomaChordoid Glioma of Third VentricleGangliocytomaAnaplastic GangliogliomaDysplastic Gangliocytoma of CerebrellumDesmoplastic Infantile Astrocytoma and GangliogliomaPapillary Glioneuronal TumorRosette-forming Glioneuronal TumorCentral NeurocytomaExtraventricular NeurocytomaCerebellar Liponeurocytoma
Summary
A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.
Eligibility
Min Age: 1 YearMax Age: 99 Years
Inclusion Criteria9
- All Subjects:
- Written informed consent, according to local guidelines, signed by the subjects and/or by the parents or legal guardian prior to any study related screening procedures are performed.
- Participation in a Novartis sponsored study such as CTMT212X2101, CDRB436G2201, CDRB436A2102, regardless of current age.
- Parent study (or cohort of parent study) is planned to be closed.
- Subject has demonstrated compliance, as assessed by the investigator, within the parent study protocol requirement(s).
- Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures.
- For Subjects Entering the Treatment Period:
- Subject is currently receiving treatment with dabrafenib/trametinib monotherapy or combination within a Novartis Sponsored Drug Development study. Note that subjects who were on the chemotherapy arm of the CDRB436G2201 study are eligible for treatment period of this study only after crossing over into the experimental treatment arm of the CDRB436G2201 study
- In the opinion of the investigator is likely to benefit from continued treatment.
Exclusion Criteria7
- All Subjects:
- \- Subject has participated in a combination trial where dabrafenib and/or trametinib was dispensed in combination with another study medication.
- For Subjects Entering the Treatment Period:
- Subject has permanently discontinued from study treatment in the parent protocol due to any reason.
- Treatment with dabrafenib and/or trametinib for the subject's indication is approved for marketing and the appropriate dosage form is commercially available and reimbursed in the local country
- Subject currently has unresolved drug related severe toxicities for which dabrafenib and/or trametinib dosing has been interrupted in the parent study. If the subject should meet criteria to resume treatment on the parent protocol then they may be eligible for treatment in this study.
- Other protocol-defined inclusion/exclusion may apply.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGdabrafenib
dabrafenib oral, twice daily
DRUGtrametinib
trametinib oral, once daily
Locations(55)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03975829
Related Trials
Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression
NCT055651181 location
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
NCT0397044763 locations
Senicapoc and Perampanel for Newly Diagnosed Glioblastoma
NCT072840691 location
A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
NCT070035421 location
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
NCT046997735 locations